Skousen’s “must have” cancer killer stock… and it’s “one of the world’s oldest, publicly traded companies”

We're teased that "Dr. Skousen just put it at the top of his Recommended List" -- what is it?

By Travis Johnson, Stock Gumshoe, November 15, 2016

This is a combo you don’t hear about very often, “founded in the 17th century” and “cancer killing blockbuster” … usually, the little biotechs that newsletters drop hints about are tiny, young, risky, sometimes fly-by-night outfits that are betting it all on a clinical breakthrough.

Not this time, apparently. So that’s why my eye was drawn to this ad for Mark Skousen’s Forecasts and Strategies newsletter (currently $49.95) — what is it that he’s teasing here?

This is the intro to the ad:

“The New ‘Jaw Dropping’ Cancer Killer that Saved a Former President’s Life!

“One of the world’s oldest, publicly traded companies – founded in the 17th century – has recently transformed itself into a ‘must have’ investment that should belong in everyone’s portfolio.

“The reason?

“The company recently stumbled upon what Cancer Research UK calls, ‘one of the greatest breakthroughs in cancer treatment in four decades’ – a cancer cure that doctors call ‘jaw dropping’!”

And apparently this company is already making money off of their discovery, and treating patients, so this isn’t brand new…

“The Profits from this Amazing New Cancer Breakthrough are Already Staggering

“This is nothing compared to what the company will earn in the months and years ahead.

“Even small shareholders could potentially make fortunes on this one stock.

“Yet, the average investor has no clue what is going on here….

“…this is the closest thing to a “can’t lose” investment I’ve ever seen.”

So what is this breakthrough? We get some more clues — this is what they say it’s already treating:

“… the FDA has already authorized use of this breakthrough cancer treatment for…

… advanced melanoma…

… non-small-cell lung cancer…

… head and neck squamous cell cancer… AND

… metastatic colorectal cancer, one of the deadliest forms of cancer.

“And that’s just the beginning.

“This treatment is so revolutionary… and prolongs life to such an unprecedented degree… it’s currently being studied for more than 30 other forms of cancers.”

And we get a blanket statement from Skousen’s publisher that probably gives us all a warm feeling inside at this particular moment in time:

“It doesn’t matter whether the economy is weak or strong, whether interest rates rise or fall, or whether the U.S. dollar goes up or down.

“It doesn’t even matter what the new administration in Washington does.

“This new cancer breakthrough could make this stock immune to troubles in the broader economy.”

Phew! OK, so here’s one where we don’t have to worry about what the next few months will bring? What a relief!

And we get the quotes from experts and other folks to buttress Skousen’s arguments, which is typical of most ads (you like to see that someone besides this newsletter guy is excited about the company, naturally):

“Science World Report calls it ‘a miracle drug.’

“The U.S. Food and Drug Administration has officially designated it a ‘breakthrough therapy.’

“The chief of medical oncology at the Yale Cancer Centre described test results on the drug as ‘spectacular.’

“And a scientist from Cancer Research UK declares that ‘the evidence emerging from clinical trials suggests that we are at the beginning of a whole new era.'”

Of course, one of the challenges of being an informed reader these days is that everything sounds official and fantastic — Science World Report is, like thousands of other websites, a collection of very brief articles, and it could well be that this is indeed a “miracle drug”… but the person who wrote that headline writes a dozen articles a day, and her most recent one is about chimpanzees who have learned to fish. The quote from the chief of medical oncology at Yale is accurate, but it was a general quote about immuno-oncology… an area of medicine in which this particular drug is one very promising and fairly early product.

So yes, we can tell you the stock — this breakthrough drug is called Keytruda and is pretty well known at this point, and was used in treating President Carter’s cancer. And the company who owns Keytruda is Merck.

Yes, Merck, the giant pharmaceutical company. So is Mark Skousen going to all this trouble to tell us to buy Merck, and implying that “small shareholders can make a fortune” just buy buying Merck shares?

We do get a few other hints:

“Since 2010, the company has generated $8 billion in free cash flow in all but one year (2014), and, in 2015, it delivered a record $11.1 billion in free cash flow.

“Early investors will soon reap the rewards….

“This anti-cancer miracle drug is not all that this pharmaceutical firm is about.

“It currently boasts 11 mid-stage programs in its pipeline (including cancer and diabetes drugs)… 25 late-stage development programs (including HIV, multiple myeloma, and roughly a half-dozen cancer types)… and five new drugs already under review by regulatory agencies.

“They include…

… new treatments for large B-cell lymphoma, diabetes and heart failure…

… vaccines to prevent ebola, herpes zoster and even HIV… and

… potential breakthroughs in the treatment of alzheimer’s disease, atherosclerosis, bacterial pneumonia and osteoporosis.”

So yes, this stock that Dr. Skousen just added “at the top of his recommended list” is indeed Merck (MRK). They were founded in the 17th century (OK, technically it was their original parent Merck that was founded back then, the US company is only 130 or so years old and has only been independent since it was nationalized in WWI). And yes, they did have $11.1 billion in free cash flow in 2015, though that was a near-term peak (the trailing twelve month free cash flow is more like $9.4 billion right now), and that is obviously a huge number that means we’re dealing with a real megacap company — Pfizer has free cash flow that’s slightly higher, Novartis is a little lower, Roche is in roughly the same neighborhood, Gilead is quite a bit higher… but that’s about it for big pharma, there aren’t many bigger names when it comes to cash flow.

Merck has a big ol’ market cap as well, it is currently valued at about $175 billion — and, as we’ve become accustomed to seeing with big pharma, it pays a nice and growing dividend, and now that they’ve survived their “patent cliff” from a few years ago they’re again growing earnings. Though, as is always the case with big pharma, there’s another patent cliff right around the corner — patent cliffs refer to the expiration dates for patents on major pharmaceutical products, since in some cases, particularly when generic versions are relatively easy to create and sell, the revenues from blockbuster drugs can fall “off a cliff” in the space of a year or less. Right now Merck is dealing with a somewhat unexpected patent cliff next year for Cubicin, the antibiotic they bought when they acquired Cubist a few years ago (they were hoping to have a few more years on that one, but lost in court), and they’re also seeing sales drop for Remicade, which has some biosimilar competition now, and will soon see generic competition for Zetia.

So Keytruda is indeed a big deal for Merck, and is expected to make up for some of that revenue drop over the next few years. Analysts do still expect Merck to grow earnings, from $3.67 this year to $3.88 next year and $4.21 in 2018, on average — so that means that investors right now are paying about 16 times next year’s earnings for Merck shares, and getting a dividend of almost 3%. That puts them pretty squarely in the middle of the pack when it comes to big pharma… it may well be that Keytruda is phenomenal and turns into a $5 billion drug instead of a $3 billion drug over the next couple years, I don’t know, but either way a small investment in Merck is not going to turn into a fortune in short order.

Will a MRK buy bring you riches? Well, maybe, but I’d guess that it will probably take a long time. The total return for MRK shares over the past decade has been about 115%, which, again, is pretty much in the middle of the “big pharma” pack, and that’s probably your best bet — that it will be a pretty solid stock in the future for long-term investors, as it has been in the past. Merck has returned about 500% over the past 20 years (including dividends), which is very impressive, and it was not a tiny company 20 years ago (it had a market cap of about $50 billion in the mid-90s), so maybe you’ll be fortunate and see returns similar to that in the decades to come… but it’s not going to generate 10,000% or 50,000% gains like Gilead or Celgene have over the past couple decades, if only because it’s already a massive and profitable company.

Keytruda is a powerful and important drug, and it is inspiring lots of other PD-1 inhibitors that will also come along and try to do a better job of boosting the immune system to fight off cancer cells, but it’s not necessarily going to create new fortunes out of thin air for Merck shareholders in the next couple years. Merck is almost the definition of a “blue chip” pharma stock and has been for decades, and assuming that it will probably have blue chip returns for a long time is probably a decent guess, absent any expert knowledge about future sales of Keytruda or the progress of their R&D of new drugs… but more than that is probably expecting too much.

Have a different opinion of Merck or Keytruda? Experience with Skousen’s Forecasts & Strategies? Other immunotherapy drugs you think are exciting that your fellow investors should hear about? Let us know with a comment below.


Are you getting our free Daily Update "reveal" emails?
If not, just click here...



Irregulars Quick Take Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)

Share your thoughts...

10 Comments on "Skousen’s “must have” cancer killer stock… and it’s “one of the world’s oldest, publicly traded companies”"

Notify of
avatar

This site uses Akismet to reduce spam. Learn how your comment data is processed.

bluesharpbob
Member
114

Coincidently, there was an interesting article in today’s NY Times about an immunotherapy drug just approved for clinical trials here that people have been going to Cuba to get. Hope this link works –

http://www.nytimes.com/2016/11/15/health/cancer-vaccine-cuba-medical-tourism.html?rref=collection%2Fsectioncollection%2Fhealth&action=click&contentCollection=health&region=rank&module=package&version=highlights&contentPlacement=1&pgtype=sectionfront&_r=0

Add a Topic
5187
curiousjoe
Irregular
27

Thanks, Blue. Great article. Cimavax was developed to combat the high rate of lung cancer, which is understandable given Cuba’s cigar industry. Workers in cigar factories smoke cigars while rolling same. (See e.g.: https://www.youtube.com/watch?v=o4QyYWf25Vg).

“Cigar tourists” to Cuba would be wise to also get some Cimavax.

Would that be an example of a “pairs trade”? 🙂

Add a Topic
4555
Add a Topic
3397
Garry
Guest
0

The link worked perfectly and most interesting. Could take the World by storm if it receives the European and USA approvals. Worth looking at this site and thanks Blue

quincy adams
Guest
0

Let’s hope Keytruda is not another Vioxx. No thanks to a certain financial advisor of yore, I had once accumulated a large quantity of Merck stock. Then along came Vioxx. I no longer have any Merck stock, or that advisor. The unkindest cut of all was that at the time, Vioxx was the only thing that worked, without nasty side effects, to relieve my wife’s arthritis pain. Fortunately, she found something cheaper and easier on the heart…red wine.

Add a Topic
5971
Add a Topic
5971
Rusty Brown in Canada
Guest
0
Rusty Brown in Canada

Been there. Had lower back pain for almost a year and Vioxx solved it, for about a month, at which point the Dr. pulled the plug on it so fast…and nothing to replace it.

Michael Jorrin,
Author
204
Agree with Travis, not surprisingly. Keytruda is a sound drug & can prolong the lives of patients with non-small cell lung cancers for maybe a year at most. Cimavax (the Cuban immunotherapy drug) is sometimes given with Keytruda. The hopes are that it will be useful in other cancers as well. Can’t comment on Merck’s prospects, nor, indeed, on the prospects of any stock. My sagacity as an investor is a bit suspect just now. Since we got out of Celgene, it has zoomed up about twenty bucks! So it goes.
Add a Topic
5187
Add a Topic
5971
dcinvest
Irregular
35

Well Skousen’s latest find must still be undiscovered by his readers as it is well down in the market yet today. KEYTRUDA has significant side effects as reported by Merck. It did have a large uptick about the 4th of November.
Travis, do you have anything on Money Morning’s latest and greatest contract with a small company that will make us all rich since all the military branches are buying? (Ala Money Morning)

Add a Topic
3415
Mike
Guest
0

So many small bio tech companies are popping up all the time, and another which holds joint patents with Merck is Provectus Pharmacueticals which has similar cancer killer in phase 3 stage, so hopefully one of these comes to market soon.

Add a Topic
3397
DrKSSMDPhD
Member
47652
I have a longstanding core position in $MRK as a rainy day stock, but I could never rank it as a “buy.” Merck has invested a fortune in devising an unusual two-drug HCV combination for HCV (combining an NS5a and a PI) called Zepatier….and this places it at risk for being tarred with the same brush as Gilead. I am not nearly as impressed or optimistic about the future of Keytruda as other posters here. Time will reveal pembrolizumab to be a very first generation drug rushed to market before investigators really understood the context of what it does fully… Read more »
Add a Topic
5971
jprovi218
Irregular
15
Dr KSS While we are on the subject of Cancer….could you please comment on the Brazilian Wasp Venom cancer peptide therapy (Polybia-MP1)? I’ve been looking for updates on this research and it seem like there is not much newly released material. Basically it only attacks malignant cells and destroys them from the outside. Once the cells are burst open they die. So far I cannot find out if any pharmaceutical companies are funding the research. There are two primary universities conducting the lead research; Sao Paula State in Brazil (Joao Ruggiero) and Leeds in England (Paul Beales) The fact that… Read more »
Add a Topic
3932
Add a Topic
3397
Add a Topic
77
wpDiscuz